Lung Cancer | Specialty

Dr. Borghaei on the Management of Immune-Related Side Effects in Lung Cancer

November 16th 2016

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the management of slightly rarer side effects that patients with lung cancer can experience when treated with immunotherapy agents.

Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC

November 16th 2016

Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer who have been treated with durvalumab.

FDA Approval Sought for Bevacizumab Biosimilar

November 16th 2016

A biologics license application (BLA) has been submitted for ABP-215, a biosimilar version of bevacizumab (Avastin), based on data from analytical, pharmacokinetic, clinical data, pharmacology, and toxicology data, according to a statement from Amgen and Allergan, the developers of the biosimilar.

Optimizing Frontline Immunotherapy in NSCLC

November 15th 2016

Immunotherapy continues to revolutionize the field of non–small cell lung cancer, with researchers now focusing on the optimal use of immune agents in the frontline setting.

Expert Discusses Next Steps With Immunotherapy in Lung Cancer

November 15th 2016

Hossein Borghaei, DO, discuss what lies ahead for immunotherapy in lung cancer, and what changes may be on the horizon for such agents as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) in the frontline setting.

Dr. Halmos on MET Mutations in Patients With NSCLC

November 15th 2016

Balazs Halmos, MD, director, Thoracic Oncology, director, Clinical Cancer Genomics, Montefiore Medical Center, discusses the prevalence of MET mutations in patients with non–small cell lung cancer (NSCLC).

Dr. West on Considering Factors for EGFR TKIs in NSCLC

November 15th 2016

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses factors he takes into consideration for EGFR tyrosine kinase inhibitors in patients who have EGFR-positive non–small cell lung cancer (NSCLC).

Sponsored Content: The Changing Paradigm of Cancer Research

November 14th 2016

Immuno-oncology is among the most discussed topics in cancer research, but many are unaware of the science behind this class of treatments. Learn how it works.

Emerging Data Could Rearrange Frontline EGFR TKIs in NSCLC

November 13th 2016

Individualizing frontline therapy for patients with non–small cell lung cancer based on preferences and clinical experience, as well as efficacy and safety data from pivotal trials, is an appropriate method for selecting EGFR-targeted agents.

Therapeutic Options Expanding for ALK-Rearranged NSCLC

November 13th 2016

The treatment landscape for patients with ALK-rearranged non–small cell lung cancer is changing rapidly, gearing up the potential for more therapeutic options to address the heterogeneity of the mechanism of resistance in this population.

Dr. Perez-Soler on Impact of Osimertinib on Field of NSCLC

November 13th 2016

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).

Dr. Anne Chiang on Molecular Testing in Lung Cancer Treatment Planning

November 13th 2016

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.

Future Directions for Antiangiogenic Therapy in Lung Cancer

November 11th 2016

Promising Anti-VEGF Combinations for NSCLC

November 11th 2016

Resistance to Antiangiogenic Therapy in Lung Cancer

November 11th 2016

Antiangiogenic Antibodies vs TKIs in NSCLC

November 11th 2016

Blocking VEGFR2 vs VEGFA or VEGFB in Lung Cancer

November 11th 2016

Sequencing Therapies in Advanced Lung Adenocarcinoma

November 11th 2016

Patient Selection for Ramucirumab in NSCLC

November 11th 2016

Mechanisms of Anti-angiogenic Therapy in Lung Cancer

November 11th 2016